Kaplan–Meier curves for PFS and OS (for patients treated with anti-PD-1/PD-L1 monotherapy). Kaplan–Meier curves for PFS and OS (for patients treated with.

Slides:

Advertisements

Similar presentations

Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 10: Survival Curves Marshall University Genomics Core.

Advertisements

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

CD25 expression is associated with unfavorable clinical outcome.

MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma Liver Cancer 2017;6: DOI: /

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

A B Yeom Supplementary Fig.2

Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.

Should Patients with Extrapulmonary Small-Cell Carcinoma Receive Prophylactic Cranial Irradiation? Jarushka Naidoo, MB BcH BAO, MRCPI, Min Yuen Teo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Mintu P. Turakhia et al. JACEP 2016;2:

Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor

High CDK6 expression predicts poor prognosis in EOC patients

Cell viability assay in NSCLC cell lines in response to gefitinib and Taxol. Cell viability assay in NSCLC cell lines in response to gefitinib and Taxol.

Supplementary Figure S1

Increase in adults treated at children's hospitals, 1999–2012, according to age group. Increase in adults treated at children's hospitals, 1999–2012, according.

Increase in adults treated at children's hospitals, 1999–2012, according to age group and disease. Increase in adults treated at children's hospitals,

A, IC50 dose–response curves of SYD985, T-DM1, and ADC isotype control in all USC cell lines tested in vitro (i.e., HER2 3+ cell lines, P =

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Fig. 3. Improved clinical responses to CD19 CAR-T cell immunotherapy after Cy/Flu lymphodepletion. Improved clinical responses to CD19 CAR-T cell immunotherapy.

Changes in tumor sizes, CA-125, serum ceruloplasmin, and copper levels in 5 patients with platinum-resistant high-grade epithelial ovarian cancer who received.

Diagnostic plots of the TGI PKPD model fitted to the A677 TGI data.

Expression analysis of IGFBP-3 using human whole-genome microarray.

Effect of HA on hematopoietic recovery in tumor-bearing mice.

MiR-520d-3p is an independent positive prognostic factor in ovarian cancer. miR-520d-3p is an independent positive prognostic factor in ovarian cancer.

Validation of the screen hits.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

CDDO-Me induces apoptosis independent of Bcl-2 level as well as p53 status in human NSCLC cells. CDDO-Me induces apoptosis independent of Bcl-2 level as.

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

Reduced BAI1 expression is associated with breast cancer patient survival. Reduced BAI1 expression is associated with breast cancer patient survival. A,

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

Accelerated metastasis spread in tumor-bearing mice treated with paclitaxel and anakinra. Accelerated metastasis spread in tumor-bearing mice treated with.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

ALDH1A3 expression levels are inversely correlated with the survival of patients with resectable mass-forming and advanced cholangiocarcinoma, respectively.

Linear correlationa between TMB cutoff for ORb for CR/PR rates and HRc for PFS, and OS depending on TMB for patients treated with anti-PD-1/PD-L1 monotherapy.

Angiogenesis in tumors formed by cells varying in the expression of CXCR2. Angiogenesis in tumors formed by cells varying in the expression of CXCR2. A,

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

The ROC curves analyzing the sensitivity and specificity of rCBVmax values in astrocytomas for 1-year survival (A) and recurrence (B) show the optimal.

A and B, The ROC curves analyzing the sensitivity and specificity of the WHO grading system (I-IV) for the 1-year survival (A) and recurrence (B) show.

Replication stress inhibition synergizes with DNA damaging agents in human cells. Replication stress inhibition synergizes with DNA damaging agents in.

A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.

Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.

Ki-67 expression in M31- and H3-treated tumors (A) and respective Ki-67 labeling indices in the two groups of tumors (B). Ki-67 expression in M31- and.

The responses of H292 and A549 lung cancer xenografts to hypofractionated radiation were enhanced by the ketogenic diet. The responses of H292 and A549.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Kaplan–Meier curves for RFS and OS by various marker groups.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. The PI3Kβ inhibitor enhances the.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Progression and survival analysis.

Venn diagram showing the overlap of PD-L1 overexpression, MSI-NGS–high, and TML-high in all gastrointestinal tumors, with all three markers tested (N =

CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.

Expression of TGFβ ligands in GBM

TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. TMEscore is a prognostic biomarker and predicts immunotherapeutic benefit. A,

STK11/LKB1 mutations are a genomic determinant of poor clinical outcome with PD-1 axis blockade in PD-L1–positive nonsquamous NSCLC, regardless of KRAS.

Cross-species computational analyses of adverse treatment response.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

Cumulative probability of CIN2 stratified by HPV test results.

STK11/LKB1 genetic alterations are associated with shorter progression-free and overall survival with PD-1 blockade among KRAS-mutant LUAC in the SU2C.

Loss of NQO1 expression inhibits invasion of NSCLC

Presentation transcript:

Kaplan–Meier curves for PFS and OS (for patients treated with anti-PD-1/PD-L1 monotherapy). Kaplan–Meier curves for PFS and OS (for patients treated with anti-PD-1/PD-L1 monotherapy). Tick marks represent patients at the time of censoring, and P values were calculated using log-rank (Mantel–Cox) test. For a similar analysis by TMB low versus intermediate to high, see Supplementary Fig. S2. A, PFS for patients with all tumor types excluding melanoma and NSCLC – TMB low to intermediate vs. high (P = 0.0033; HR 0.35; 95% CI, 0.19–0.64). For TMB low to intermediate, N = 40 with 35 events. For TMB high, N = 15 with 8 events. B, PFS for patients with all tumor types, including melanoma and NSCLC – TMB low to intermediate vs. high (P = 0.0005; HR 0.36; 95% CI, 0.23–0.58). For TMB low to intermediate, N = 80, with 66 events. For TMB high, N = 22 with 12 events. C, PFS for patients with melanoma or NSCLC – TMB low to intermediate vs. high (P = 0.0402; HR = 0.36; 95% CI, 0.17– 0.77). For TMB low to intermediate, N = 40 with 31 events. For TMB high, N = 7 with 4 events. D, OS for patients with all tumor types excluding melanoma and NSCLC – TMB low to intermediate vs. high for all tumor types excluding melanoma and NSCLC (P = 0.2836; HR 0.59; 95% CI, 0.25–1.40). For TMB low to intermediate, N = 40 with 20 events. For TMB high, N = 15 with 5 events. E, OS for patients with all tumor types, including melanoma and NSCLC – TMB low to intermediate vs. high (P = 0.0557; HR 0.44; 95% CI, 0.23–0.87). For TMB low to intermediate, N = 80 with 36 events. For TMB high, N = 22 with 6 events. F, OS for patients with melanoma or NSCLC – TMB low to intermediate vs. high (P = 0.0926; HR 0.21; 95% CI, 0.07–0.63). For TMB low to intermediate, N = 40 with 16 events. For TMB high, N = 7 with one events. CI, confidence interval. Aaron M. Goodman et al. Mol Cancer Ther 2017;16:2598-2608 ©2017 by American Association for Cancer Research